445 related articles for article (PubMed ID: 19959491)
1. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
2. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
3. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
6. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement.
Akinci B; Comlekci A; Ali Ozcan M; Demir T; Yener S; Demirkan F; Yuksel F; Yesil S
Endocr J; 2007 Feb; 54(1):45-52. PubMed ID: 17090955
[TBL] [Abstract][Full Text] [Related]
7. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
9. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
10. The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
Ozeren M; Karahan SC; Ozgur M; Eminagaoglu S; Unsal M; Baytan S; Bozkaya H
Acta Obstet Gynecol Scand; 2005 Oct; 84(10):987-91. PubMed ID: 16167916
[TBL] [Abstract][Full Text] [Related]
11. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
12. [Study of fibrinolysis inhibitors in 117 acute leukemia patients].
Wang W; Ji CY; Ye JJ; Zhu YY; Guo DM; Ji M
Zhonghua Xue Ye Xue Za Zhi; 2008 Mar; 29(3):183-6. PubMed ID: 18788619
[TBL] [Abstract][Full Text] [Related]
13. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
14. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia.
Verkleij CJ; Stuijver DJ; van Zaane B; Squizzato A; Brandjes DP; Büller HR; Meijers JC; Gerdes VE
Thromb Haemost; 2013 Feb; 109(2):214-20. PubMed ID: 23197299
[TBL] [Abstract][Full Text] [Related]
16. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
17. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation.
Chen CC; Lee KD; Gau JP; Yu YB; You JY; Lee SC; Hsu HC; Chau WK; Ho CH
Ann Hematol; 2005 Oct; 84(10):675-80. PubMed ID: 16007424
[TBL] [Abstract][Full Text] [Related]
18. Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population.
Santamaría A; Borrell M; Oliver A; Ortín R; Forner R; Coll I; Mateo J; Souto JC; Fontcuberta J
Am J Hematol; 2004 Aug; 76(4):348-52. PubMed ID: 15282667
[TBL] [Abstract][Full Text] [Related]
19. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
20. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease.
Van Thiel DH; George M; Fareed J
Thromb Haemost; 2001 Apr; 85(4):667-70. PubMed ID: 11341503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
